📊 NAGE Key Takeaways
Is NAGE a Good Investment? Thesis Analysis
Niagen Bioscience exhibits exceptional fundamental strength with 29.9% revenue growth, net income nearly doubling YoY, and outstanding 64.3% gross margins typical of specialty pharma products. The balance sheet is fortress-like with $64.8M cash (61% of assets), minimal 0.13x debt/equity, and 22.7% ROE, demonstrating both profitability and financial stability.
Why Buy NAGE? Key Strengths
- Net income growth (103.3% YoY) significantly outpacing revenue growth (29.9% YoY) indicates improving operational leverage and margin expansion
- Exceptional cash position of $64.8M with minimal debt ($10.1M LT debt) and 4.86x current ratio provides substantial financial flexibility and zero solvency risk
- Outstanding profitability with 64.3% gross margin and 13.4% net margin, plus exceptional returns (22.7% ROE, 16.3% ROA) indicating strong competitive positioning in medicinal chemicals sector
- Strong free cash flow generation ($13.4M FCF, 10.3% FCF margin) with minimal capital requirements ($147K capex) demonstrates capital-efficient business model
NAGE Investment Risks to Consider
- Small revenue base ($129.4M) creates concentration risk and limits scale advantages; sustainability of 29.9% growth unproven beyond single reporting period
- Operating cash flow ($13.5M) trails net income ($17.4M) by $1.9M, suggesting potential working capital management needs or quality-of-earnings concerns requiring monitoring
- Minimal insider buying activity (3 Form 4 filings in 90 days) provides no conviction signal from management regarding valuation or outlook
- Biotech/specialty pharma sector subject to FDA regulatory changes, pricing pressures, and potential product obsolescence risks
Key Metrics to Watch
- Quarterly revenue and net income trends to confirm sustainability of 29.9% and 103.3% YoY growth rates
- Gross margin stability - maintaining 64.3% margin is critical to thesis; any erosion below 60% would signal competitive or pricing pressure
- Operating cash flow vs net income gap - ensure cash generation remains robust and working capital doesn't deteriorate
- Cash burn runway and return on accumulated cash - monitor if cash position is efficiently deployed or if it signals lack of growth investment opportunities
NAGE Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.86x current ratio provides a solid financial cushion.
NAGE Profitability Ratios
NAGE vs Default Sector
How Niagen Bioscience, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NAGE Overvalued or Undervalued?
Based on fundamental analysis, Niagen Bioscience, Inc. appears fundamentally strong relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NAGE Balance Sheet & Liquidity
NAGE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Niagen Bioscience, Inc.'s revenue has grown significantly by 92% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.11 reflects profitable operations.
NAGE Growth Metrics (YoY)
NAGE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $25.6M | $1.4M | $0.02 |
| Q2 2025 | $22.7M | -$15.0K | $0.00 |
| Q1 2025 | $22.2M | -$492.0K | $-0.01 |
| Q3 2024 | $19.5M | -$959.0K | $-0.01 |
| Q2 2024 | $20.3M | -$15.0K | $0.00 |
| Q1 2024 | $22.2M | -$492.0K | $-0.01 |
| Q3 2023 | $17.1M | -$959.0K | $-0.01 |
| Q2 2023 | $16.7M | -$2.2M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NAGE Capital Allocation
NAGE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Niagen Bioscience, Inc. (CIK: 0001386570)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NAGE
What is the AI rating for NAGE?
Niagen Bioscience, Inc. (NAGE) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NAGE's key strengths?
Claude: Net income growth (103.3% YoY) significantly outpacing revenue growth (29.9% YoY) indicates improving operational leverage and margin expansion. Exceptional cash position of $64.8M with minimal debt ($10.1M LT debt) and 4.86x current ratio provides substantial financial flexibility and zero solvency risk.
What are the risks of investing in NAGE?
Claude: Small revenue base ($129.4M) creates concentration risk and limits scale advantages; sustainability of 29.9% growth unproven beyond single reporting period. Operating cash flow ($13.5M) trails net income ($17.4M) by $1.9M, suggesting potential working capital management needs or quality-of-earnings concerns requiring monitoring.
What is NAGE's revenue and growth?
Niagen Bioscience, Inc. reported revenue of $129.4M.
Does NAGE pay dividends?
Niagen Bioscience, Inc. does not currently pay dividends.
Where can I find NAGE SEC filings?
Official SEC filings for Niagen Bioscience, Inc. (CIK: 0001386570) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NAGE's EPS?
Niagen Bioscience, Inc. has a diluted EPS of $0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NAGE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Niagen Bioscience, Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NAGE stock overvalued or undervalued?
Valuation metrics for NAGE: ROE of 22.7% (sector avg: 15%), net margin of 13.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy NAGE stock in 2026?
Our dual AI analysis gives Niagen Bioscience, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NAGE's free cash flow?
Niagen Bioscience, Inc.'s operating cash flow is $13.5M, with capital expenditures of $147.0K. FCF margin is 10.3%.
How does NAGE compare to other Default stocks?
Vs Default sector averages: Net margin 13.4% (avg: 12%), ROE 22.7% (avg: 15%), current ratio 4.86 (avg: 1.8).